216 related articles for article (PubMed ID: 33927108)
1. Next-generation sequencing for the management of sarcomas with no known driver mutations.
Vyse S; Thway K; Huang PH; Jones RL
Curr Opin Oncol; 2021 Jul; 33(4):315-322. PubMed ID: 33927108
[TBL] [Abstract][Full Text] [Related]
2. Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience.
Cote GM; He J; Choy E
Oncologist; 2018 Feb; 23(2):234-242. PubMed ID: 28860410
[TBL] [Abstract][Full Text] [Related]
3. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.
Groisberg R; Roszik J; Conley A; Patel SR; Subbiah V
Curr Oncol Rep; 2017 Oct; 19(12):78. PubMed ID: 29030741
[TBL] [Abstract][Full Text] [Related]
4. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
5. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
6. Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.
Hensley ML; Chavan SS; Solit DB; Murali R; Soslow R; Chiang S; Jungbluth AA; Bandlamudi C; Srinivasan P; Tap WD; Rosenbaum E; Taylor BS; Donoghue MTA; Hyman DM
Clin Cancer Res; 2020 Jul; 26(14):3881-3888. PubMed ID: 32299819
[TBL] [Abstract][Full Text] [Related]
7. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
8. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
9. Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?
Italiano A
Curr Treat Options Oncol; 2018 Dec; 19(12):78. PubMed ID: 30523434
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of sarcomas: new vistas for precision medicine.
Al-Zaid T; Wang WL; Somaiah N; Lazar AJ
Virchows Arch; 2017 Aug; 471(2):243-255. PubMed ID: 28664413
[TBL] [Abstract][Full Text] [Related]
11. Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss.
Lazo de la Vega L; Hovelson DH; Cani AK; Liu CJ; McHugh JB; Lucas DR; Thomas DG; Patel RM; Tomlins SA
Hum Pathol; 2016 Dec; 58():161-170. PubMed ID: 27664537
[TBL] [Abstract][Full Text] [Related]
12. The clinical utility of next-generation sequencing for bone and soft tissue sarcoma.
Gusho CA; Weiss MC; Lee L; Gitelis S; Blank AT; Wang D; Batus M
Acta Oncol; 2022 Jan; 61(1):38-44. PubMed ID: 34686105
[No Abstract] [Full Text] [Related]
13. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
[TBL] [Abstract][Full Text] [Related]
14. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
15. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
17. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.
Kasago IS; Chatila WK; Lezcano CM; Febres-Aldana CA; Schultz N; Vanderbilt C; Dogan S; Bartlett EK; D'Angelo SP; Tap WD; Singer S; Ladanyi M; Shoushtari AN; Busam KJ; Hameed M
Mod Pathol; 2023 Aug; 36(8):100165. PubMed ID: 36990277
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden.
Ak M; Kahraman A; Arnold FM; Turko P; Levesque MP; Zoche M; Ramelyte E; Dummer R
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34202213
[TBL] [Abstract][Full Text] [Related]
19. Targeting DNA repair: the genome as a potential biomarker.
Nesic K; Wakefield M; Kondrashova O; Scott CL; McNeish IA
J Pathol; 2018 Apr; 244(5):586-597. PubMed ID: 29282716
[TBL] [Abstract][Full Text] [Related]
20. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
